Overview

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to establish the safety and efficacy of a combination of Erbitux (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Treatments:
Cetuximab
Gemcitabine